Strategy and TPP

SCIO

BBCR’s experienced team in Regulatory Affairs FDA and EMA assists clients in simplifying complex and evolving regulatory processes.

November 30th, 2022 | Strategy and TPP

BBCR specializes in taking the complexity inherent to the regulatory phase of the approvals and simplifying it by strategizing our support to each client based on product-specific regulatory requirements and functional needs. Our expertise spans: Regulatory Strategy FDA Meeting & Submission Pre-IND Integrated Development Plan Regulatory Submissions  

BBCR uses innovative approaches to de-risk your product development. For our clients interested in Proof of Mechanism and Proof of Concept – PoM and PoC – Our team has the expertise to ensure successful product development at any stage of development.

November 28th, 2022 | Strategy and TPP
PoM and PoC Services Boston Biotech Clinical Research

The BBCR team designs Proof of Concept (PoC) Trials and Proof of Mechanism (PoM) studies with the drug clinical plan and regulatory strategy in mind. Proof of Mechanism (PoM) Usually in Healthy Volunteers, Phase 1 study Essential for the selection of appropriate dose for PoC, disease model and biomarkers Investigate drug concentration at the target […]

Clinical trials are time-consuming, expensive, and often burdensome on patients. Clinical trials can fail for many reasons. Our experience provides an understanding of these reasons and offers insights into opportunities for improving the likelihood of creating and executing successful clinical trials.

November 16th, 2022 | Strategy and TPP

The Trial Management That Addresses Risks Experienced management address risks such as: Delayed enrollment Multiple protocol amendments Poor patient retention Poor data quality Prolonged trial completion timeline Poor safety monitor Let BBCR Consulting assist in your clinical trial strategy. Reach out to us to learn more about how we can help.

SCIO assists with early stage biotech company evaluation. Learn why adopting this clinical roadmap and development strategy is critical to your success in bringing your product to market.

October 28th, 2022 | Strategy and TPP

How can SCIO SM help? To enhance your position, it becomes crucial to demonstrate that your product/technology is the “safe” option for investment and a stand-out opportunity by including a clinical roadmap and development strategy of your product/technology. This roadmap illuminates clearly for the investment team what the target indications will be and the paths […]

Efficiencies in clinical research have become essential in the areas of trial management and trial rescue

October 26th, 2022 | Strategy and TPP

Every clinical study has its unique challenges that initially may not have been factored for.  Experienced management can help sponsors to address prolonged trial timeline and data quality. Rare Diseases and Precision Medicine require unique approaches to trial execution and data quality. There could be any number of factors that could necessitate a study being […]

BBCR specializes in taking the complexity inherent to the regulatory phase of the approvals and simplifying it by strategizing our support to each client based on product-specific regulatory requirements and functional needs.

October 17th, 2022 | Strategy and TPP

BBCR can assist clients in the following areas: Regulatory Strategy Thinking ahead during the regulatory process, we avoid unnecessary hurdles in the approvals process. We identify gaps, work through the right strategies for an effective product application, and prepare for label claims. FDA Meeting & Submission Critical to the success of bringing your product to […]

BBCR supports innovative and repurposing treatments for orphan diseases.

October 4th, 2022 | Strategy and TPP

Developing innovative or repurposing drugs for orphan diseases can be rewarding, but navigating the challenges is not for the faint of heart. Expert guidance is essential in an area where patients are few; a lack of previous studies may hamper progress as you mount an orphan petition and negotiate a clinical plan with the FDA. […]

BBCR provides expert development guidance for Orphan Disease. The BBCR mission is to customize strategies, simplify clinical research, design cost-effective trials, streamline protocols, and create a regulatory roadmap.

September 28th, 2022 | Strategy and TPP

As one of the first consultancy teams to streamline clinical trials, BBCR’s boutique consulting team specializes in rare disease and orphan indications dedicated to supporting pharmaceutical innovators, and nurturing each product’s strengths. The BBCR Team provides knowledge in cell, biologics and gene therapies BBCR addresses sponsors’ questions in the ever-changing regulatory environment Clinical strategy for […]

BBCR offers Translational Medicine and Biomarkers Program Consultation to bridge the gap between pre-clinical and early clinical development

September 21st, 2022 | Strategy and TPP

Translational medicine is a bridge between pre-clinical and early clinical development (from bench to bedside), creating the foundation for precision medicine in late clinical development. A translational medicine program includes the adoption of biomarkers to mitigate clinical trials risk, identify patient subpopulations, facilitate decision-making, and accelerate drugs’ market approval.  

The BBCR mission is to customize strategies, simplify clinical research, design cost-effective trials, streamline protocols, and create a regulatory roadmap. Learn more about our services by visiting bbcrconsulting.com

September 20th, 2022 | Strategy and TPP

How we can help The BBCR team provides knowledge in cell, biologics and gene therapies BBCR addresses sponsors’ questions in the ever-changing regulatory environment We offer clinical strategy for orphan diseases and precision medicine RWE can be used to build orphan diseases evidence to support regulatory decisions BBCR serves small and medium sized Biotech Companies, […]

Pin It on Pinterest